SCHEMBL2223282

SCHEMBL2223282

Nc1cccc(Cc2nn(-c3ccccc3)ccc2=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.43
PARP1 P09874 1/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.39
GAA P10253 1/20 0.39
POLB P06746 2/20 0.39
ABHD6 Q9BV23 2/20 0.39
MGLL Q99685 1/20 0.39
ELOVL1 Q9BW60 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL255722 0.93 PARP1 (0.41) CYP2C9PARP1MAOAMAOBALDH1A1
SCHEMBL13275315 0.86 PARP1 (0.39) PARP1MAOAMAOBALDH1A1ABHD6
SCHEMBL13274914 0.86 PARP1 (0.37) CYP2C9PARP1ALDH1A1HTTABHD6
SCHEMBL13275429 0.85 PARP1 (0.38) CYP2C9PARP1MAOAMAOBALDH1A1
SCHEMBL13274755 0.85 GRM5 (0.44) PARP1ADORA2ACYP11B1CYP11B2
SCHEMBL13506827 0.84 CYP2C9 (0.43) CYP2C9PARP1ALDH1A1HTTGAA
SCHEMBL2269403 0.84 CYP2C9 (0.47) CYP2C9PARP1ALDH1A1HTTGAA
SCHEMBL13505244 0.84 GAA (0.45) CYP2C9ALDH1A1HTTGAAPOLB
SCHEMBL13275009 0.84 PARP1 (0.37) CYP2C9PARP1ALDH1A1POLBABHD6
SCHEMBL173258 0.82 PARP1 (0.38) CYP2C9PARP1ALDH1A1ABHD6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 CYP2C9 4808/4885PARP1 2307/4885MAOA 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.